Project Grant RF1AG079867
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$2.1M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to investigate the role of sex differences and brain angiotensin II activation in Alzheimer's disease (AD) pathogenesis and cognitive impairment. The $3,558,527 award to the University of North Texas Health Science Center at Fort Worth aims to elucidate the mechanisms by which sex chromosomes, sex hormones, and brain-derived hormones interact to influence angiotensin II-associated...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $459,250 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on the impact of stress and resilience on Alzheimer's disease pathology and cognitive function. The 2-year project aims to investigate the longitudinal relationship between stress, resilience, Alzheimer's pathology (amyloid-beta and tau), and cognitive outcomes using data...
The National Institute on Aging (NIA) awarded a $125,896 Project Grant under the Aging Research program (CFDA 93.866) to The Washington University in St. Louis to conduct research on Alzheimer's disease (AD) risk and resilience pathways. The project aims to perform deep molecular characterization of AD genetic risk factors and protective mechanisms using state-of-the-art single-cell multi-omic analyses of healthy and AD human brain tissue, as well as transgenic AD mouse models. Key objectives...
This $427,625 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866). The grant was awarded to The Washington University in St. Louis to support research evaluating novel transcription factors that regulate astrocyte identity, reactivity, and their roles in the pathogenesis of Alzheimer's disease (AD) and Parkinson's disease (PD). The research aims to systematically evaluate 10 candidate transcription factors identified...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $245,434 to Wake Forest University Health Sciences to examine the associations between early and later-life stress on later-life cognition and plasma biomarkers of Alzheimer's disease and related dementias (ADRD). The project aims to cross-sectionally analyze the relationship between life course stress and cognition or ADRD biomarkers, including amyloid-beta, tau proteins, and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $349,605.00 to Stress Therapeutics, Inc. to advance the development of a novel therapeutic candidate for the long-term management of Alzheimer's disease (AD) and other conditions characterized by hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis. The primary objectives are to optimize a lead compound, establish stable cell lines for production, and lay the foundations for future...
This $427,625 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to elucidate the mechanisms by which microgliopathy, a genetic neurological disorder, causes early-onset dementia. The research will investigate how the loss of the DAP12 protein in microglia, the immune cells of the brain, leads to heightened signaling of the RUNX and STAT3 pathways. This dysregulation is hypothesized to disrupt normal microglial functions and induce brain pathology and...
This Project Grant award of $654,238 from the National Institute on Aging (CFDA 93.866 Aging Research program) supports research to identify the role of senescent neurons in brain aging and Alzheimer's disease and related dementias (ADRD). The primary awardee, the University of Texas Health Science Center at San Antonio, will generate spatial omics data from ADRD brains and mouse models, while the co-investigator team at Washington University will provide expertise in experimental design, data...
This $6,226,692 Project Grant awarded by the National Institute on Aging (NIA) under the Aging Research (CFDA 93.866) program supports research examining the role of neuronal hyperexcitability and proteostasis in the progression of Alzheimer's disease (AD). The study aims to use a mouse model to investigate how modifications in brain activity, specifically in the locus coeruleus (LC) and hippocampus (HPC), can lead to the pathological hallmarks of AD. Key objectives include tracking early...
The National Institutes of Health National Institute on Aging awarded $3,024,000 under the Aging Research federal grant program (CFDA 93.866) to the Massachusetts General Hospital on September 30, 2022 for a project concluding on August 31, 2025. The award will support research into discovering sex-linked genes on the inactive X chromosome that may influence female vulnerability to Alzheimer's disease pathology. The awardee will employ genomic, transcriptomic, and epigenetic analysis to...